Friday 16 October 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.06
0.06
+6.00%
Follow ALXO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(118.95%) | (145.70%) | (74.17%) | (80.65%) | |
| (80.47%) | (98.34%) | (59.40%) | (63.16%) | ||
ROIC |
0.00% | 0.00% | (291.68%) | (673.30%) | |
Return on Tangible Assets |
(269.05%) | (371.50%) | (70.29%) | (62.78%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.82) | (1.57) | (0.75) | (0.52) | |
Free Cash Flow |
(97.43) | (84.35) | (78.33) | (70.91) | |
Capital Expenditures |
(0.22) | (0.21) | (0.20) | (0.13) | |
| Other line items | |||||
Cash ROIC |
(84.33%) | (104.76%) | (26.09%) | (24.96%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(67.81) | (64.93) | (59.70) | (58.67) | |
Operating CF/Net income |
0.90 | 0.83 | 0.88 | 0.88 | |
Depreciation/Fixed assets |
(0.55) | (0.21) | 0.01 | (0.77) | |
Capex/Depreciation |
0.30 | 0.83 | (18.36) | 1.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.81) | (1.57) | (0.75) | (0.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates